The Next Billion-Dollar Acquisition in Pharma -

Gene Quinn is the president and founder of IPWatchdog.com, a patent attorney, law professor, and leading commentator on patent law and innovation policy. Gene’s writings typically focus on pending legislation, rule making at the United States Patent and Trademark Office, and general commentary about the state of the industry. Gene practices patent law with Widerman Malek, and the majority of his patent practice is focused on software patents and Internet innovations. Since 2000 he has also been a principal lecturer in the PLI Patent Bar Review Course.

Marco is the Head of Consulting & Customer Success at PatentSight – A LexisNexis Company. Marco has a strong consulting background in patent analytics, providing insights in dozens of projects to Fortune 500 and DAX companies. As a strategic consultant he has guided the transition of many patent departments to turn from an administrative patent function into an internal consulting unit. With PatentSight’s deep understanding of customer needs and challenges, he empowers his team to transfer this knowledge into our global customer community.  “PatentSight Customer Success goes a great distance to understand our business and our pain points. Their support is outstanding and they really help us generating value” – quote from a recent customer survey that summarizes the work of PatentSight’s Consulting & Customer Success team.

Kevin E. Noonan is a partner with McDonnell Boehnen Hulbert & Berghoff LLP and serves as Chair of the firm’s Biotechnology & Pharmaceuticals Practice Group. An experienced biotechnology patent lawyer, Dr. Noonan brings more than 20 years of extensive work as a molecular biologist studying high-technology problems in serving the unique needs of his clients. His practice involves all aspects of patent prosecution, interferences, and litigation. He represents pharmaceutical companies both large and small on a myriad of issues, as well as several universities in both patenting and licensing to outside investors. He has also filed amicus briefs in landmark patent and other cases to district courts, the Federal Circuit and the U.S. Supreme Court involving patenting issues relevant to biotechnology.